Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥142.00 - ¥432.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥3.02B
Enterprise Value¥608.57M
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-58.44
Shares Outstanding18,429,500
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthA clear multi-year revenue uptrend (doubling from 2021–2026) indicates sustained commercial traction and market demand for the company’s offerings. That durable top-line growth creates a foundation to spread fixed costs, improve operating leverage and support longer-term margin improvements if cost discipline follows.
High Gross ProfitabilityStrong gross margins imply attractive unit economics and product-level pricing power, giving the company structural room to fund R&D and SG&A while still moving toward EBIT breakeven. Durable gross profitability strengthens the path to sustainable margins as revenue scales and fixed costs are absorbed.
Conservative Balance Sheet (no Debt)An absence of reported debt reduces financial risk and interest burden, preserving strategic flexibility for product investment or partnerships. Substantial assets and positive equity provide a durable buffer while the company executes commercialization, lowering short-to-medium term solvency risk.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow forces reliance on external capital and raises dilution and financing risk. Although burn improved in 2026, the company still consumed large cash amounts, meaning financing needs and constraints on strategic investments will persist unless cash generation reverses.
Large Operating Losses Vs RevenueSubstantial operating losses relative to sales indicate the company has not yet converted gross profitability into positive operating profit. This structural gap means even with revenue growth, the business must materially reduce operating expense intensity or materially scale sales to reach sustainable profitability.
Material Equity ErosionA multi-year decline in equity reflects cumulative losses and likely dilution, shrinking the company’s capital cushion. Continued erosion reduces strategic optionality, can worsen fundraising terms, and signals persistent value destruction that undermines long-term shareholder outcomes.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥142.00 and its highest was ¥432.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.02B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 48 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on May 14, 2026. The company reported -¥11.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.03.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 18,429,500 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---